A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
Latest Information Update: 18 Sep 2024
At a glance
- Drugs Aflibercept (Primary) ; Sozinibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms COAST
- Sponsors Opthea
- 09 Jul 2024 According to an Opthea media release, topline data from this trial expected in early Q2 2025
- 28 May 2024 According to an Opthea media release, pivotal 52-weeks topline data expected in mid-CY2025 to support a potential BLA submission.
- 01 May 2024 According to an Opthea media release, company announced that scientific presentations on the sozinibercept (OPT-302) from ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida.